Pembrolizumab, xantoastrocitoma, xanthoastrocytoma

https://braintumorcenter.ucsf.edu/clinical-trial/study-pembrolizumab-mk-3475-pediatric-participants-advanced-solid-tumor-or-lymphoma

• RECRUITING 
 
• PEDIATRICS 
 
• ON HOLD 

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Conditions

Glioma

 

Astrocytoma

 

Pleomorphic xanthoastrocytoma (grades II-III)

 

Pilocytic astrocytoma (grade I)

 

Brainstem Glioma

Diffuse Midline Glioma

 

Atypical Teratoid / Rhaboid Tumor (AT/RT)

 

Ependymoma

 

Medulloblastoma

Summary

The purpose of this Phase I/II clinical trial is to evaluate the dosage, safety and efficacy of pembrolizumab in treating pediatric participants with any of the following types of cancer:

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Conditions

Glioma

 

Astrocytoma

 

Pleomorphic xanthoastrocytoma (grades II-III)

 

Pilocytic astrocytoma (grade I)

 

Brainstem Glioma

Diffuse Midline Glioma

 

Atypical Teratoid / Rhaboid Tumor (AT/RT)

 

Subependymal giant cell astrocytoma (grade I)

 

Medulloblastoma

Choroid Plexus Tumors

The purpose of this Phase I clinical trial is to evaluate the safety and efficacy of the drug ramucirumab, in treating children with recurrent or refractory solid tumors, including CNS tumors.

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Conditions

Glioma

 

Astrocytoma

 

Pleomorphic xanthoastrocytoma (grades II-III)

 

Pilocytic astrocytoma (grade I)

 

Brainstem Glioma

Diffuse Midline Glioma

 

Atypical Teratoid / Rhaboid Tumor (AT/RT)

 

Subependymal giant cell astrocytoma (grade I)

Choroid Plexus Tumors

 

Medulloblastoma

The purpose of this Phase I clinical trial is to study the side effects and best dose of entinostat in treating pediatric patients with recurrent or refractory solid tumors.

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

Conditions

Glioma

 

Astrocytoma

 

Pleomorphic xanthoastrocytoma (grades II-III)

 

Pilocytic astrocytoma (grade I)

 

Brainstem Glioma

Diffuse Midline Glioma

 

Medulloblastoma

 

Choroid Plexus Tumors

 

Atypical Teratoid / Rhaboid Tumor (AT/RT)

The purpose is to evaluate cognitive, social, emotional, and behavioral functioning over time in patients already enrolled in a Children’s Oncology Group Phase III clinical trial.

Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors

Conditions

Glioma

 

Astrocytoma

 

Pleomorphic xanthoastrocytoma (grades II-III)

 

Pilocytic astrocytoma (grade I)

 

Brainstem Glioma

Diffuse astrocytoma (grade II)

 

Ependymoma

 

Medulloblastoma

 

Pituitary Tumor

This Phase I clinical trial will assess the safety and tolerability of hyperpolarized pyruvate for metabolic imaging in children with brain tumors.

Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions

Conditions

Glioma

 

Astrocytoma

 

Pleomorphic xanthoastrocytoma (grades II-III)

 

Brainstem Glioma

 

Diffuse astrocytoma (grade II)

Medulloblastoma

 

Atypical Teratoid / Rhaboid Tumor (AT/RT)

The purpose of this Phase I clinical trial is to evaluate the safety, dosage, and efficacy of entrectinib in treating children and young adults with solid tumors, primary CNS tumors, and neuroblastoma.

Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas

Conditions

Glioma

 

Astrocytoma

 

Pilocytic astrocytoma (grade I)

 

Pleomorphic xanthoastrocytoma (grades II-III)

 

Glioblastoma (grade IV)

This trial is testing the drug vemurafenib (also called PLX4032) in children with pediatric astrocytomas that have the BRAFV600E mutation. Vemurafenib works by blocking the activity of BRAF, a key protein in the RAS/RAF/MAPK pathway that is overactive in these tumors.

WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Conditions

Medulloblastoma

 

Glioma

 

Astrocytoma

 

Pleomorphic xanthoastrocytoma (grades II-III)

 

Pilocytic astrocytoma (grade I)

Brainstem Glioma

 

Diffuse Midline Glioma

 

Ependymoma

 

Metastatic Brain Tumor

The purpose of this Phase I/II clinical trial is to study the side effects and best dose of irinotecan hydrochloride in combination with MK-1775 to treat pediatric patients with recurrent or refractory solid tumors.

https://www.mayoclinic.org/diseases-conditions/astrocytoma/diagnosis-treatment/clinical-trials/rsc-20320219

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients

1. Rochester, Minn., Jacksonville, Fla.
   The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after radiation and temozolomide chemotherapy.

2. Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

   Rochester, Minn., Scottsdale/Phoenix, Ariz.
   This phase II trial studies the side effects and how well pembrolizumab works in combination with standard therapy in treating patients with glioblastoma. Drugs used in the chemotherapy, such as pembrolizumab and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving pembrolizumab and standard therapy comprising of temozolomide and radiation therapy may kill tumor cells.